Advertisement

Breast Cancer

, 3:25 | Cite as

Suppression of estrogenic activity by medroxyprogesterone acetate in tamoxifen-treated patients after surgery for breast cancer to reduce the risk of endometrial cancer development

  • Hiroyoshi Doihara
  • Shigemitsu Takashima
  • Akira Kurita
  • Shosuke Moriwaki
Original Article
  • 24 Downloads

Abstract

Background

Postoperative adjuvant tamoxifen (TAM) therapy in breast cancer patients may lead, albeit rarely, to endometrial cancer. Preventive measures are urgently needed.

Methods

The study subjects were postmenopausal women who had undergone surgery for breast cancer. The control group (n=10) received no further therapy. Patients who had completed adjuvant TAM therapy were assigned to a medroxy-progesterone acetate (MPA; 400 mg/day orally for 4 weeks) group (n=15) or no MPA treatment group (no MPA group) (n=15). Uterine cervix cytodiagnosis was performed after completing the TAM therapy (initial), and 4 (4-week) and 16 (16-week) weeks later. The serum 17β-estradiol (E2) and progesterone concentrations were measured initially and at 4 weeks. The karyopyknotic index (KPI), eosinophilic index (EI) and maturation index (MI) were calculated from Papanicolaou-stained specimens.

Results

The background parameters showed no biases. There were no differences in the KPI or EI between the no MPA and MPA groups. However, regarding the MI, after 4 weeks in the MPA group, the intermediate cells were significantly increased, while the superficial cells tended to be significantly decreased. Regarding the percent change from the initial value, after 4 weeks in the MPA group, the KPI and superficial cells were significantly decreased, and the intermediate cells were significantly increased. The estrogen activity level and the progesterone concentration were significantly lower in the MPA group compared with the no MPA group. Conclusions. The MPA administration clearly lowered the estrogenic activity, indicating that MPA therapy should be effective in reducing the risk of TAM-associated endometrial cancer.

Key words

Tamoxifen Medroxyprogesterone acetate Breast cancer Endometrial cancer 

Abbreviations

TAM

Tamoxifen

MPA

Medroxyprogesterone acetate

E2

17β-Estradiol

KPI

Karyopyknotic index

EI

Eosinophilic index

MI

Maturation index

References

  1. 1).
    Nolvadex Adjuvant Trial Organisation (NATO): Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer.Br J Cancer 57:608–611, 1988.Google Scholar
  2. 2).
    Boccardo F, Bruzzi P, Rubagotti A,et al: Estrogen- like action of tamoxifen on vaginal epithelium in breast cancer patients.Oncology 38:281–285, 1981.PubMedCrossRefGoogle Scholar
  3. 3).
    Boccardo F, Guarneri D, Rubagotti A,et al: Endocrine effects of tamoxifen in postmenopausal breast cancer patients.Tumori 70:61–68, 1984.PubMedGoogle Scholar
  4. 4).
    Ziel HK, Finkle WD: Increased risk of endometrial carcinoma among users of conjugated estrogens.N Engl J Med 293:1167–1170, 1975.PubMedGoogle Scholar
  5. 5).
    Malfetano JH: Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients.Gynecol Oncol 39:82–84, 1990.PubMedCrossRefGoogle Scholar
  6. 6).
    De Muylder X, Neven P, De Somer M,et al: Endometrial lesions in patients undergoing tamoxifen therapy.Int J Gynecol Obstet 36:127–130, 1991.CrossRefGoogle Scholar
  7. 7).
    Gal D, Kopel S, Bashevkin M.et al: Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer; Preliminary report.Gynecol Oncol 42:120–123, 1991.PubMedCrossRefGoogle Scholar
  8. 8).
    Teshima H, Ikenaga M, Yokosuka K,et al: Does long- term administration of tamoxifen cause the endometrial adenocarcinoma in breast cancer patients after operation?J Clin Exp Med 154:509–510, 1990.Google Scholar
  9. 9).
    Hardell L: Tamoxifen as risk factor for carcinoma of corpus uteri.Lancet 2:563, 1988.PubMedCrossRefGoogle Scholar
  10. 10).
    Fornander T, Cedermark P, Mattsson A,et al: Adjuvant tamoxifen in early breast cancer; Occurrence of new primary cancers.Lancet 2:117–120, 1989.CrossRefGoogle Scholar
  11. 11).
    Mathew A, Chabon AB, Kabakow B,et al: Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy.NY State J Med 90:207- 208, 1990.Google Scholar
  12. 12).
    Killackey MA, Hakes TB, Pierce VK, Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens.Cancer Treat Rep 69:237–238, 1985.PubMedGoogle Scholar
  13. 13).
    Atlante G, Pozzi M, Vincenzoni C,et al: Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma.Gynecol Oncol 37:378–380, 1990.PubMedCrossRefGoogle Scholar
  14. 14).
    Cole MB, Jones CT, Todd IDH: A new antiestrogenic agent in late breast cancer; An early clinical approach of ICI 146474.Br J Cancer 25:270–275, 1971.PubMedGoogle Scholar
  15. 15).
    Hoover R, Fraumeni JF, Everson R,et al: Cancer of the uterine corpus after hormonal treatment for breast cancer.Lancet 1:885–887, 1976.PubMedCrossRefGoogle Scholar
  16. 16).
    Anzai Y, Holinka CF, Kuramoto H,et al: Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line).Cancer Res 49:2362–2365, 1989.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 1996

Authors and Affiliations

  • Hiroyoshi Doihara
    • 1
  • Shigemitsu Takashima
    • 1
  • Akira Kurita
    • 1
  • Shosuke Moriwaki
    • 2
  1. 1.Department of Surgery IIOkayama University Medical SchoolOkayamaJapan
  2. 2.PathologyShikoku Cancer Center HospitalOkayamaJapan

Personalised recommendations